Adicet Bio (ACET) to Release Earnings on Tuesday

Adicet Bio (NASDAQ:ACET) will likely be posting its quarterly earnings results before the market opens on Tuesday, March 18th. Analysts expect Adicet Bio to post earnings of ($0.36) per share for the quarter.

Adicet Bio (NASDAQ:ACET) last announced its earnings results on Thursday, March 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.05. On average, analysts expect Adicet Bio to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Adicet Bio Stock Performance

Shares of NASDAQ:ACET opened at $0.78 on Friday. The stock has a market capitalization of $64.71 million, a price-to-earnings ratio of -0.46 and a beta of 1.97. The stock’s 50-day simple moving average is $0.91 and its two-hundred day simple moving average is $1.13. Adicet Bio has a 52-week low of $0.74 and a 52-week high of $2.43.

Analysts Set New Price Targets

ACET has been the topic of several research reports. HC Wainwright reissued a “neutral” rating on shares of Adicet Bio in a research report on Friday, March 7th. StockNews.com cut Adicet Bio from a “hold” rating to a “sell” rating in a research report on Tuesday, November 19th. Finally, JMP Securities reissued a “market perform” rating on shares of Adicet Bio in a research report on Thursday, February 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $7.50.

About Adicet Bio

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.